Treatment prediction by subset analysis of tumor infiltrating lymphocytes (TILs) in combination therapy with trastuzumab, pertuzumab, and docetaxel for advanced HER2-positive breast cancer

被引：0
|
作者：
Takada, Koji [1 ]
Kashiwagi, Shinichiro [1 ]
Asano, Yuka [1 ]
Wataru, Goto [1 ]
Morisaki, Tamami [1 ]
Noda, Satoru [1 ]
Takashima, Tsutomu [1 ]
Onoda, Naoyoshi [1 ]
Hirakawa, Kosei [1 ]
Ohira, Masaichi [1 ]
机构：
[1] Osaka City Univ, Grad Sch Med, Osaka, Japan
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3119
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3119
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [2] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [3] Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
    Liu, Yan-cui
    Ma, Ying
    An, Ning
    Sun, Ping
    Wang, Ying
    Sun, Cheng
    MEDICINE, 2019, 98 (38)
  • [4] Tumor infiltrating lymphocytes as a predictive factor in Pertuzumab/Trastuzumab-treated HER2-positive breast cancer
    Saito, Kanako
    Kotsuka, Yuji
    Oda, Hiroyasu
    Ishihara, Mikiya
    Tamaru, Satoshi
    Yamashita, Yoshiki
    Mizuno, Toshiro
    Katayama, Naoyuki
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [6] Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer
    Takada, Koji
    Kashiwagi, Shinichiro
    Goto, Wataru
    Asano, Yuka
    Morisaki, Tamami
    Fujita, Hisakazu
    Takashima, Tsutomu
    Ohsawa, Masahiko
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2018, 38 (04) : 2285 - 2294
  • [7] Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer
    Kashiwagi, Shinichiro
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Takahashi, Katsuyuki
    Hatano, Takaharu
    Takashima, Tsutomu
    Tomita, Shuhei
    Motomura, Hisashi
    Ohsawa, Masahiko
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2017, 37 (10) : 5623 - 5630
  • [8] Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review
    Ventura, Ignacio
    Salcedo, Nerea Pinilla
    Perez-Bermejo, Marcelino
    Perez-Murillo, Javier
    Tejeda-Adell, Manuel
    Tomas-Aguirre, Francisco
    Legidos-Garcia, Maria Ester
    Murillo-Llorente, Maria Teresa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [9] Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
    Luen, Stephen J.
    Salgado, Roberto
    Fox, Stephen
    Savas, Peter
    Eng-Wong, Jennifer
    Clark, Emma
    Kiermaier, Astrid
    Swain, Sandra M.
    Baselga, Jose
    Michiels, Stefan
    Loi, Sherene
    LANCET ONCOLOGY, 2017, 18 (01): : 52 - 62
  • [10] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Dwan, Kerry
    Dickson, Rumona
    Proudlove, Chris
    Dundar, Yenal
    PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23
12345